Extracting β-amyloid from Alzheimer's disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 9, 2012, Pages 3199-3200

  Dries, Daniel R ^a   Yu, Gang ^a   Herz, Joachim ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; GAMMA SECRETASE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; NOTCH RECEPTOR; WITHANIA SOMNIFERA EXTRACT;

ALZHEIMER DISEASE; NERVE DEGENERATION; NERVE FIBER GROWTH; NONHUMAN; NOTE; PLANT ROOT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; LIVER; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MALE; PHYTOTHERAPY; PLANT EXTRACTS; WITHANIA;

EID: 84857726331     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1121560109     Document Type: Note

References (19)

1. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297:353-356. (Pubitemid 34790756)
2. Sehgal N, et al. (2012) Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci USA 109:3510-3515.
3. Kuboyama T, Tohda C, Komatsu K (2005) Neuritic regeneration and synaptic reconstruction induced by withanolide A. Br J Pharmacol 144:961-971. (Pubitemid 40593022)
4. Kuboyama T, Tohda C, Komatsu K (2006) Withanoside IV and its active metabolite, sominone, attenuate Abeta(25-35)-induced neurodegeneration. Eur J Neurosci 23:1417-1426.
5. Herz J, et al. (1988) Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J 7:4119-4127.
6. Dries DR, Yu G (2008) Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease. Curr Alzheimer Res 5:132-146. (Pubitemid 351536338)
7. De Strooper B, Vassar R, Golde T (2010) The secretases: Enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 6:99-107.
8. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101-112. (Pubitemid 46432529)
9. Dasilva KA, Shaw JE, McLaurin J (2010) Amyloid-beta fibrillogenesis: Structural insight and therapeutic intervention. Exp Neurol 223:311-321.
10. Wang YJ, Zhou HD, Zhou XF (2006) Clearance of amyloid-beta in Alzheimer's disease: Progress, problems and perspectives. Drug Discov Today 11:931-938.
11. Lemere CA, Masliah E (2010) Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 6:108-119.
12. St George-Hyslop PH, Morris JC (2008) Will anti-amyloid therapies work for Alzheimer's disease? Lancet 372:180-182.
13. Deane R, Bell RD, Sagare A, Zlokovic BV (2009) Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 8:16-30.
14. Sagare A, et al. (2007) Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 13:1029-1031. (Pubitemid 47517512)
15. Nalivaeva NN, Fisk LR, Belyaev ND, Turner AJ (2008) Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 5:212-224. (Pubitemid 351536346)
16. Dieckmann M, Dietrich MF, Herz J (2010) Lipoprotein receptors - an evolutionarily ancient multifunctional receptor family. Biol Chem 391:1341-1363.
17. Selkoe DJ (2011) Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 17:1060-1065.
18. Wang YJ, Zhou HD, Zhou XF (2010) Modified immunotherapies against Alzheimer's disease: Toward safer and effective amyloid clearance. J Alzheimers Dis 21:1065-1075.
19. Pollen DA, et al. (2010) Prevention of Alzheimer's disease in high risk groups: Statin therapy in subjects with PSEN1 mutations or heterozygosity for apolipoprotein E epsilon 4. Alzheimers Res Ther 2:31.